首页 News 正文

On January 12th local time, Merck announced that the US Food and Drug Administration (FDA) has approved the use of Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemotherapy (CRT) for the treatment of stage III-IVA cervical cancer patients defined by the International Federation of Obstetrics and Gynecology (FIGO) 2014.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

我放心你带套猛 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    31